The U.S. Centers for Disease Control and Prevention (CDC) on Aug. 3 recommended using a new monoclonal antibody from Sanofi and AstraZeneca to protect infants against respiratory syncytial virus (RSV).
The CDC’s advisory committee voted unanimously to include the nirsevimab antibody drug, called Beyfrotus, in the Vaccines for Children program, which will provide access to Beyfrotus at no cost to eligible children.
